GentiBio Launches with $20M Seed Funding from OrbiMed, Novartis Venture Fund and RA Capital Management, L.P. to Develop Engineered Regulatory T cells to Deliver Immune Tolerizing Therapies for Autoimmune and Inflammatory Diseases

Additionally, GentiBio's platform will enable the scaled production of robust EngTregs cell therapy products that are antigen specific and tunable.